Biotechnology company Advanced Enzyme Technologies announced Q1FY27 results Consolidated Financial Highlights: Revenue from operations: For Q1FY27, revenue stood at Rs 1,897.88 million, reflecting a YoY increase of 2.08% from Rs 1,859.14 million in Q1FY26. On a QoQ basis, it decreased by 6.68% compared to Rs 2,033.67 million in Q4FY26. Total Income: Total income reached Rs 2,028.09 million in Q1FY27, an increase of 4.13% from Rs 1,947.64 million in Q1FY26, while declining by 3.70% from Rs 2,105.95 million in Q4FY26. Profit Before Tax: The company reported a profit before tax of Rs 535.26 million in Q1FY27, a decrease of 2.50% YoY from Rs 549.00 million in Q1FY26 and a 10.50% decrease QoQ from Rs 598.04 million in Q4FY26. Net Profit: Net profit for the period Q1FY27 was Rs 385.89 million, down 4.58% YoY from Rs 404.40 million in Q1FY26 and down 14.72% QoQ from Rs 452.52 million in Q4FY26. Standalone Financial Highlights: Revenue from operations: In Q1FY27, revenue was Rs 1,158.57 million, representing a YoY decline of 7.33% from Rs 1,250.24 million in Q1FY26 and a marginal QoQ decrease of 0.48% from Rs 1,164.10 million in Q4FY26. Total Income: Standalone total income for Q1FY27 was Rs 1,181.44 million, reflecting a YoY decrease of 33.95% from Rs 1,788.76 million in Q1FY26 and a QoQ decrease of 2.82% from Rs 1,215.73 million in Q4FY26. Profit Before Tax: Standalone profit before tax for Q1FY27 was Rs 297.41 million, a decrease of 63.46% YoY compared to Rs 813.96 million in Q1FY26, but an increase of 3.11% QoQ from Rs 288.43 million in Q4FY26. Net Profit: For Q1FY27, net profit stood at Rs 223.46 million, down 69.80% YoY from Rs 739.81 million in Q1FY26, but recording a slight QoQ growth of 0.23% from Rs 222.95 million in Q4FY26. Business Highlights: Segment Performance: The Group operates exclusively in one business segment, which is "manufacturing and sales of enzymes". Equity Share Buyback: The Board approved a buyback of fully paid-up equity shares (face value Rs 2 each) at a price not exceeding Rs 500 per share via the "Open Market" route for an aggregate amount not exceeding Rs 697 million. This buyback represents 9.99% and 5.09% of the total paid-up equity share capital and free reserves on a standalone and consolidated basis, respectively. The indicative maximum number of equity shares to be bought back is 1,394,000. Acquisition of JC Biotech Private Limited (JCB): Approval was granted to acquire the remaining 4.28% stake (886,544 equity shares) from existing shareholders for a total consideration of Rs 79.79 million. Upon completion of this acquisition, JCB (previously a 95.72% subsidiary) will become a wholly-owned subsidiary of the company. Fund Infusion in Advanced Nutrazyme Private Limited (ANPL): The Board approved an infusion of additional funds not exceeding Rs 20 million into ANPL, a wholly-owned subsidiary, through equity investment or inter-corporate deposits for business purposes. Exceptional Items: For the prior year ended March 31, 2026, standalone results included an incremental impact of Rs 38.58 million primarily due to change in wage definitions following the notification of the four Labour Codes. Dividend: A final dividend of Rs 1.35 per equity share for the financial year 2025-26 was paid to shareholders on August 5, 2026. Result PDF